Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Chemotherapy for Rectal Cancer with Suboptimal Response
NCT01941979Phase 3Unknown
- Sponsor
- Instituto do Câncer do Estado de São Paulo
- Start
- Sep 2011
- Primary completion
- Sep 2015
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of oxaliplatin, fluorouracil, capecitabine in rectal adenocarcinoma, sponsored by Instituto do Câncer do Estado de São Paulo. Status: unknown.
02
Drugs
oxaliplatinfluorouracilcapecitabine
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT01941979.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01941979.